Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours

Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours

(2011) Daniel Kaemmerer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

‘Reverse discordance’ between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan

(2011) Sandip Basu et al.   NUCLEAR MEDICINE COMMUNICATIONS

The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors

(2010) Andrea Frilling et al.   ANNALS OF SURGERY

Standardized Uptake Values of 68Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors

(2010) D. Campana et al.   JOURNAL OF NUCLEAR MEDICINE

68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors

(2010) V. Ambrosini et al.   JOURNAL OF NUCLEAR MEDICINE

The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy

(2010) R. Srirajaskanthan et al.   JOURNAL OF NUCLEAR MEDICINE

68Ga-DOTA-NOC PET/CT Imaging of Neuroendocrine Tumors: Comparison with 111In-DTPA-Octreotide (OctreoScan®)

(2010) Yodphat Krausz et al.   MOLECULAR IMAGING AND BIOLOGY

Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours

(2009) V. Zamora et al.   DIGESTIVE AND LIVER DISEASE

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

(2009) Dik J Kwekkeboom et al.   ENDOCRINE-RELATED CANCER

Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy

(2009) D. Putzer et al.   JOURNAL OF NUCLEAR MEDICINE

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT

(2008) Matthias Miederer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors

(2008) Amani Asnacios et al.   JOURNAL OF CLINICAL ONCOLOGY

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY